Mangoceuticals (MGRX) Equity Average (2023 - 2026)

Mangoceuticals has disclosed Equity Average across 4 years of filings, most recently posting $14.3 million for Q1 2026.

• Equity Average for Q1 2026 came in at $14.3 million, down 16.14% year-over-year; the trailing twelve-month figure through Mar 2026 was $14.3 million (down 16.14% YoY), and the FY2025 annual result was $14.6 million, up 98.0% from the prior year.
• Equity Average came in at $14.3 million for Q1 2026 at Mangoceuticals, down from $15.5 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $19.7 million in Q2 2025 to a low of -$91857.0 in Q1 2024.
• The 4-year median for Equity Average is $13.8 million (2024), against an average of $9.8 million.
• Across the five-year window, Equity Average slumped 104.14% in 2024 and surged 18713.56% in 2025, its largest moves.
• Mangoceuticals' Equity Average stood at $1.1 million in 2023, then surged by 1204.21% to $13.9 million in 2024, then gained by 11.36% to $15.5 million in 2025, then declined by 7.28% to $14.3 million in 2026.
• The last three Equity Average figures came in at $14.3 million (Q1 2026), $15.5 million (Q4 2025), and $17.5 million (Q3 2025), per Business Quant data.